Theme: "AI-based Drug Discovery and Precision Medicine Innovation"
The AI BIO Conference 2025, an international conference exploring the future of medicine through the convergence of artificial intelligence (AI) and biotechnology, will be held on November 7 at Gyeongwonjae in Songdo International City, Incheon.
Under the theme "AI-based Drug Discovery and Precision Medicine Innovation," the event will bring together global researchers to present solutions on how AI is transforming the entire field of life sciences, including drug discovery, cancer diagnostics, proteomics, and spatial biology.
First, Professor Taehyun Hwang of Vanderbilt University in the United States will deliver a keynote speech on "AI-based 3D/4D Molecular and Spatial Biology," outlining how AI can reinterpret life phenomena at the molecular level and drive medical innovation. Professor Hwang is the founding director of the Molecular AI Initiative, which leads research in molecular life sciences using AI, and is recognized as a world-leading expert in AI-based cancer diagnostics and precision medicine.
Next, Siyoun Lee, Ph.D., co-founder and president of the Korean-American Life Scientists Exchange Association (K-BioX) and a researcher at Stanford University, will present on "The Future of the Global AI-Bio Collaborative Ecosystem." In particular, plans will be discussed to establish a foundation for global research, entrepreneurship, and talent exchange centered around Incheon in the future.
Additionally, Professor Hansik Han of the University of Cambridge in the United Kingdom will deliver a keynote speech on "AI & Drug Discovery." As one of the leading authorities in AI-driven drug discovery and development, he will share the latest trends on how AI is revolutionizing traditional drug development processes.
Leading global experts in cancer research will also gather in Songdo. Dr. Andrew H. Song, a Harvard University Ph.D. and member of the MD Anderson Cancer Center, along with Professor Younghwan Jang of Oregon Health & Science University, have been invited to give lectures sharing the most innovative research findings in precision medicine, including AI-based cancer diagnostics and multimodal biological data analysis.
A global cooperation session for AI-Bio innovation will also be held, presenting strategic directions to expand the Incheon Free Economic Zone into an AI-Bio collaboration platform connecting Asia and North America. Key players in the AI-bio industrial ecosystem-such as Samsung Biologics, LG AI Research, Lotte Biologics, and Celltrion-will attend to discuss collaborative models between industry, academia, research, and hospitals, as well as cases of industrial application of AI-Bio technologies.
Yoon Wonseok, Commissioner of the Incheon Free Economic Zone Authority, stated, "The convergence of AI and biotechnology is not just a technological innovation, but a paradigm shift that will transform human life and health. With leading scholars driving next-generation life science innovation coming together, this event will mark the first step for Incheon to become a global AI-Bio hub."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
